New Delhi: Catalent Inc cut its full-year net revenue and profit forecast on Friday, reflecting operational challenges and higher-than-expected costs after it flagged an over $400 million hit to ...
Franco Origlia / Contributor / Getty Images Catalent shares jumped on positive comments about its business. The company said it still needs more time to complete its fiscal Q3 earnings report.
The logo of the Catalent plant is seen outside their location where millions of doses of the AstraZeneca coronavirus disease (COVID-19) vaccine were reportedly found in Anagni, Italy, March 24 ...
Catalent trimmed its annual revenue and net income forecasts. The contract drug manufacturer said the cuts were due to operational challenges. Catalent said it continues to add new customers. It ...
Contract drug manufacturer Catalent (ticker: CTLT) delivered more bad news on Friday, but investors shrugged it off, securing the stock a top place in the S&P 500. The company said it will again ...
Catalent Inc. shares rose after the troubled contract drug manufacturer gave investors some reassurance about a slashed ...
Catalent's financials are still past due, but investors are looking forward. The pharmaceuticals contract manufacturer said Friday it is unable to file its financial results with the SEC for the ...
(Reuters) -Contract drug manufacturer Catalent Inc on Friday slashed its full-year forecasts for profit and sales and delayed its quarterly results for the third time, bruised by a series of ...
Catalent cut its full-year sales and earnings outlook to reflect higher-than-expected costs and operational challenges. The contract drug manufacturer said it now expects fiscal 2023 sales of $4. ...
Analysts say the events over the past weeks may have hurt takeover interest in Catalent. Danaher Corp. shelved a potential offer in April, after earlier making overtures that valued the company at a ...
